Gilead reports ‘very strong quarter’ despite slipping Veklury sales

Gilead CEO Dan O’Day uncorked some solid Q2 results on Tuesday, touting a surge in Yescarta and Trodelvy sales and an uptick in demand for HIV med Biktarvy. Will sinking Covid sales spoil the party?

Johanna Mercier

Veklury sales were down 48% last quarter, topping...

Click to view original post